Companion Animal Welfare

Cat Feline Immune Disease Advanced 2026

Advanced feline immune disease management in 2026 integrates targeted immunosuppression, monitoring protocols, and emerging biologics for better welfare outcomes.

Key Facts

Targeted IL-31 biologics are in development for feline atopic dermatitis in 2026
Mycophenolate mofetil provides steroid-sparing immunosuppression with fewer side effects
Calcineurin inhibitors (cyclosporine) are effective for skin and GI immune-mediated disease
Regular monitoring of complete blood count and biochemistry guides dose adjustment
Novel biomarkers for feline immune activation enable more precise treatment monitoring

Welfare Considerations

Advanced immune disease management in 2026 offers cats significantly better welfare outcomes through targeted biologics, steroid-sparing agents, and precise monitoring. Reducing treatment side effects while maintaining disease control is the welfare goal of modern immunosuppressive management.

What You Can Do

Discuss steroid-sparing alternatives with your vet for cats on long-term prednisolone
Ask about emerging biologics for feline atopic dermatitis if conventional treatments are inadequate
Ensure regular monitoring of immune-suppressed cats for secondary infections